KP-1461
KP-1461 is an experimental antiretroviral drug that was under development for the treatment of HIV/AIDS. It belongs to a class of drugs known as viral mutagens, which work by inducing high rates of mutation in the HIV virus, thereby causing it to self-destruct.
Mechanism of Action
KP-1461 works by inducing a process known as viral error catastrophe or lethal mutagenesis. This process involves the introduction of a high rate of mutations into the genetic material of the virus, which leads to the production of nonviable offspring and ultimately, the collapse of the viral population.
The drug is a nucleoside reverse transcriptase inhibitor (NRTI), which means it interferes with the action of reverse transcriptase, an enzyme that HIV uses to replicate its genetic material. However, unlike other NRTIs, KP-1461 is designed to increase, rather than decrease, the rate of mutation during this process.
Clinical Trials
KP-1461 has undergone Phase I and Phase II trials. The results of these trials suggested that the drug was well-tolerated and had a favorable safety profile. However, the drug did not show a significant reduction in viral load, which led to the discontinuation of its development.
Potential Advantages and Disadvantages
One of the potential advantages of KP-1461 is that it could overcome the problem of drug resistance, which is a major challenge in the treatment of HIV/AIDS. By causing the virus to self-destruct, the drug could potentially be effective against all strains of HIV, including those that have developed resistance to other antiretroviral drugs.
However, the approach of inducing lethal mutagenesis also carries potential risks. For example, there is a concern that the high rate of mutation could lead to the emergence of more virulent or drug-resistant strains of the virus. In addition, the long-term effects of such a high rate of mutation on the host's cells are unknown.
See Also
- Antiretroviral drug
- Viral mutagen
- HIV/AIDS
- Viral error catastrophe
- Nucleoside reverse transcriptase inhibitor
- Drug resistance
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD